Lyra Therapeutics Inc Net Income per Employee (LYRA), current and historic results, rankings and more, Quarterly Fundamentals - CSIMarket
CSIMarket
 


Lyra Therapeutics Inc   (NASDAQ: LYRA)
 

Lyra Therapeutics Inc Net Income per Employee

LYRA's Quarterly Results, Trends, Rankings, Statistics
Lyra Therapeutics Inc recorded a cumulative net loss of $-29 million during 12 month ending in the fourth quarter 2025.
The Healthcare sector has seen employees of 185 other companies achieving higher income per employee. While Lyra Therapeutics Inc 's total ranking has deteriorated compared to the previous quarter from 3797 to 3959.


What is Income per Employee Ratio?






LYRA Net Income per Employee (Dec 31 2025)
IV. Quarter
(Sep 30 2025)
III. Quarter
(Jun 30 2025)
II. Quarter
(Mar 31 2025)
I. Quarter
(Dec 31 2024)
IV. Quarter
Y / Y Net Income Change - - - - -
Net Income per Employee (TTM) $ -1,071,074 -1,220,259 -1,438,370 -2,945,556 -3,460,556
LYRA's Total Ranking # 3959 # 3797 # 2972 # 2172 # 2819
Seq. Net Income Change - - - - -


LYRA Net Income per Employee Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 186
Healthcare Sector # 675
Overall Market # 3959

Net Income per Employee Statistics
High Average Low
$ -156,741 $ -2,000,593 $ -3,755,185
(Mar 31 2020)   (Jun 30 2024)







Companies with similar Income per Employee for 12 month ending Dec 31 2025, within Healthcare Sector Income per Employee Income 12 month ending Dec 31 2025Number of Employees Dec 31 2025


Date modified: 2026-07-07T12:01:06+00:00




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.